news

Aug 19, 2021

Boston Scientific starts recruitment for randomized controlled trials for the EkoSonic™ Endovascular System On August 04, 2021, Boston Scientific Corporation started the enrolment in the HI-PEITHO clinical trial, which is a collaborative research study with the Pulmonary Embolism Response Team (PERT) Cons...

Aug 17, 2021

FDA’s Green Flag to Keytruda and Lenvima combination by Merck and Eisai for Advanced renal cell carcinoma (RCC) The FDA approved the combination of Keytruda and Lenvima produced by Merck and Eisai, as a first-line treatment of adult patients with advanced renal cell carcinoma (RCC). The efficacy and safety resul...

Aug 12, 2021

LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with USD 19 million.  The two-year-old Canadian biotech will utiliz...

Aug 05, 2021

Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acq...

Aug 03, 2021

Nevro Received FDA Approval of its 10 kHz High-Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy On July 19, 2021, Nevro Corp. received approval for its Senza System, Nevro's unique 10 kHz stimulation, to treat chronic pain associated with Painful...

Jul 29, 2021

Teneobio and its next-gen cancer work acquired by Amgen  Amgen has penned a major new buyout deal to boost its oncology pipeline further. The biopharma is putting USD 900 million down upfront, with USD 1.6 billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibod...

Jul 27, 2021

Alzheimer's Association International Conference (AAIC) 2021 Opens With Thrilling Details of Pharmas and Powerful Therapeutic Discoveries  The most awaited Alzheimer’s Association International Conference 2021 (AAIC) commenced yesterday on July 26th, 2021 in Denver, Colorado, which was presented both virtua...

Jul 22, 2021

BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapy BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enroll ten patients across the US and Canada, with its prima...

Jul 08, 2021

UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Advanced Vascular Eye Disease patients  UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to decrease, impede, or reverse diseases of aging, declared positive data from its Phase 1 safety study of U...

Jul 06, 2021

Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial  Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of ARO-ENaC for patients with cystic fibrosis (CF). The announcement came after a preliminary update from an ongoing chronic ...